Validation of UAS7 among children with chronic spontaneous urticaria

The Urticaria Activity Score and its summed score over 7 days (UAS7) are the validated guideline-recommended reference standards for disease activity for adults with chronic spontaneous urticaria (CSU).1 However, the UAS7 remains to be validated in children. The Children’s Dermatology Life Quality Index (CDLQI) is a questionnaire used to estimate quality of life2 and has been validated for use in chronic urticaria for ages 4 years and older.3 We aimed to validate the use of UAS7 in children presenting with CSU through assessment of correlation with the CDLQI score, through the assessment of the effect of increased antihistamine dose on UAS7, and through evaluation of the association between high UAS7 in children and the need for omalizumab.